 |
|
|
|
|
|
|
|
|
|
|
|
1 to 23 of 23 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Golde T. on NEWS: Microglia and AD—Does the Inflammasome Drive Aβ Pathology?, It is likely that innate immune activation can have positive or negative effects on proteostasis... 21 Dec 2012.
|
|
|
 |
|
|
Golde T. on PAPER: Ebke A. et al., 2011, My take is that this is fundamentally sound but that some GSMs clearly interact with substrate.... 16 Sep 2011.
|
|
|
|
|
|
Golde T. on PAPER: O'Nuallain B. et al., 2010, I remain agnostic as to what studies of in vitro toxicity tell us about pathogenic mechanisms in... 10 Nov 2010.
|
|
|
|
|
|
Golde T. on NEWS: AD Clinical Pipeline: Immunotherapy Woes, Dimebon Boons, The recent follow-up to the AN1792 study by Holmes et al. is a thought-provoking study that... 23 Jul 2008.
|
|
|
|
|
|
Golde T. on LIVE DISCUSSION: Gain or Loss of Function—Time to Shake up Assumptions on γ-Secretase in Alzheimer Disease?, With respect to Dr. Davies's comments, I think first and foremost we have to consider the fact... 19 Apr 2006.
|
|
|
|
|
|
Golde T. on NEWS: Early Events in AD Mice as Targets for Therapy, I think we in this field have to be careful with overinterpreting phenomena in our APP mouse... 19 Apr 2006.
|
|
|
|
|
|
Golde T. on NEWS: SfN: Channeling Selective Toxicity in Parkinson Disease, This is a very interesting story, but assumes a widespread underlying premise that is incorrect.... 19 Dec 2005.
|
|
|
|
|
|
Golde T. on NEWS: SfN: R-Flurbiprofen Phase 2 Trial Results, It is important to clarify the statement "Flurbiprofen is the only approved NSAID still in the... 19 Dec 2005.
|
|
|
|
|
|
Golde T. on PAPER: Zhou S. et al., 2005, The recent manuscript by Zhou et al. clearly shows that CD147 co-purifies with the γ-secretase... 17 May 2005.
|
|
|
|
|
|
Golde T. on NEWS: FRETting Pays off—NSAIDs Target Presenilins, Reduce Aβ42, The findings are significant for three main reasons:
First: They provide strong evidence... 30 Sep 2004.
|
|
|
|
|
|
Golde T. on PAPER: Andorfer C. et al., 2003, This could be the best model for studying AD like tauopathies, as these mice develop tangles... 3 Aug 2003.
|
|
|
|
|
|
Golde T. on PAPER: Etminan M. et al., 2003, Recommendation Only. 3 Aug 2003.
|
|
|
|
|
|
Golde T, Koo E. on NEWS: Naproxen/Rofecoxib Trial Results Published, The study by Aisen et al. shows no benefit to rofecoxib or naproxen in patients with mild to... 9 Jun 2003.
|
|
|
|
|
|
Golde T. on PAPER: Bard F. et al., 2003, This is a study on a quite impressive scale that compares different isotypes of anti-Abeta... 19 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Ikeuchi T. et al., 2003, The data presented here are similar to that presented at recent meetings by Taylor Kimberly,... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Koldamova RP. et al., 2003, Another paper suggesting with data that support the notion that changes in cellular cholesterol... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Bennett DA. et al., 2003, Clinical-Pathologic data that supports the hypothesis that APOE4 casues AD by influencing Abeta... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Schott JM. et al., 2003, Another nice study from this group. These longitudinal data provide insight into the rates of... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Pype S. et al., 2003, A straightforward study further documenting the complexity of Abeta production and deposition. ... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Qi Y. et al., 2003, This study is arguably the most comprehensive study of FAD-linked PS mutations with respect to... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on PAPER: Redwine JM. et al., 2003, The is an interesting and somewhat unexpected finding. At 100 days of age PDAPP mice show a... 17 Feb 2003.
|
|
|
|
|
|
Golde T. on NEWS: Presenilin—Guilty of Proteolysis by Association?, In a collaboration initiated by Chris Ponting, we have also identified the family of proteins... 1 Jul 2002.
|
|
|
|
|
|
Golde T. on NEWS: NO-Releasing NSAID Reduces b-Amyloid, Activates Microglia, In humans, a substantial body of evidence suggests NSAIDs confer some protection from AD. ... 18 Mar 2002.
|
|
|
|
|
|
|
1 to 23 of 23 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
